← Back to Screener
OnKure Therapeutics, Inc. Class A Common Stock (OKUR)
Price$4.19
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)31.28%
Price vs S&P 500 (4W)7.17%
VGM Score80.54
Market Capitalization$169.26M
All Metrics
Book Value / Share (Quarterly)$4.56
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.26
Price vs S&P 500 (YTD)36.33%
EPS (TTM)$-4.33
10-Day Avg Trading Volume0.40M
EPS Excl Extra (TTM)$-4.33
EPS (Annual)$-4.40
ROI (Annual)-105.93%
Cash / Share (Quarterly)$4.76
ROA (Last FY)-95.81%
EBITD / Share (TTM)$-4.50
ROE (5Y Avg)-64.60%
Cash Flow / Share (Annual)$-3.79
P/B Ratio0.92x
P/B Ratio (Quarterly)0.31x
Net Income / Employee (Annual)$-1,322,600
ROA (TTM)-55.99%
EPS Incl Extra (Annual)$-4.40
Current Ratio (Annual)10.28x
Quick Ratio (Quarterly)13.41x
3-Month Avg Trading Volume0.28M
52-Week Price Return46.50%
Revenue / Employee (TTM)$0
52-Week High$5.38
EPS Excl Extra (Annual)$-4.40
CapEx CAGR (5Y)18.13%
26-Week Price Return39.20%
Quick Ratio (Annual)9.97x
13-Week Price Return32.59%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.78x
Enterprise Value$-22.85M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.32
3-Month Return Std Dev84.51%
Net Income / Employee (TTM)$-1,305,500
ROE (Last FY)-105.93%
EPS Basic Excl Extra (Annual)$-4.40
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.33
ROI (TTM)-61.02%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)22.14%
Year-to-Date Return44.48%
5-Day Price Return-0.24%
EPS Normalized (Annual)$-4.40
ROA (5Y Avg)-57.50%
Month-to-Date Return-0.24%
EBITD / Share (Annual)$-4.62
ROI (5Y Avg)-64.60%
EPS Basic Excl Extra (TTM)$-4.33
P/B Ratio (Annual)0.70x
Book Value / Share (Annual)$4.11
Price vs S&P 500 (13W)24.34%
Beta0.30x
Revenue / Share (TTM)$0.00
ROE (TTM)-61.02%
52-Week Low$1.91
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-1.11est. -0.76
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OKUROnKure Therapeutics, Inc. Class A Common Stock | — | — | A | $4.19 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing precision cancer medicines that target biologically validated disease drivers in underserved indications. The company focuses on oncology areas with limited existing treatment options.